Enanta Pharmaceuticals to Participate at the Jefferies Global Healthcare Conference
Enanta Pharmaceuticals to Participate at the Jefferies Global Healthcare Conference
WATERTOWN, Mass.--(BUSINESS WIRE)--May 29, 2024-- Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA), a clinical-stage biotechnology company dedicated to creating small molecule drugs for virology and immunology indications, today announced that Jay R. Luly, Ph.D., President and Chief Executive Officer, and Tara L. Kieffer, Ph.D., Chief Product Strategy Officer, will participate in a fireside chat at the Jefferies Global Healthcare Conference on June 5, 2024 at 7:30 a.m. ET in New York, NY.
馬薩諸塞州沃特敦-（商業資訊）-2024年5月29日-Enanta製藥有限公司。（NASDAQ: ENTA）是一家臨床階段的生物技術公司，致力於創造用於病毒學和免疫學指示的小分子藥物。今天日，該公司宣佈Jay R. Luly博士，總裁兼首席執行官和Tara L. Kieffer博士，首席產品戰略官將於2024年6月5日美國東部標準時間上午7:30在紐約的傑富瑞環球衛生保健大會上舉行爐邊聊天。
A live webcast of the event will be accessible by visiting the "Events and Presentations" section on the "Investors" page of Enanta's website at www.enanta.com. A replay of the webcast will be available following the presentation and will be archived for at least 30 days.
本次活動的現場網絡直播可訪問Enanta網站“投資者”頁面下的“活動和演示文稿”部分。www.enanta.com。演示文稿的重播將在演示結束後提供，並將存檔至少30天。演示結束後，將提供網絡播放的重播，並將存檔至少30天。
About Enanta Pharmaceuticals, Inc.
關於Enanta製藥公司
Enanta is using its robust, chemistry-driven approach and drug discovery capabilities to become a leader in the discovery and development of small molecule drugs for virology and immunology indications. Enanta's research and development programs are currently focused on respiratory syncytial virus (RSV) and chronic spontaneous urticaria (CSU) and the company has previously advanced clinical-stage compounds for SARS-CoV-2 (COVID-19) and chronic hepatitis B virus (HBV) infection.
Enanta使用其強大的化學驅動方法和藥物發現能力，致力於成爲病毒學和免疫學指示的小分子藥物發現和開發領域的領導者。Enanta的研發項目目前集中於呼吸道合胞病毒(RSV)和慢性自發性蕁麻疹(CSU)，並且該公司以前已將臨床階段的化合物推廣至嚴重急性呼吸綜合症冠狀病毒2型（COVID-19）和慢性乙型肝炎病毒（HBV）感染。Enanta發現的一種蛋白酶抑制劑Glecaprevir是治療慢性丙型肝炎病毒感染的療法之一，Abbvie以MAVYRET(U.S.)和MAVIRET(ex-U.S.)(glecaprevir/pibrentasvir)爲貿易名稱在許多國家銷售。Enanta從與AbbVie合作開發的丙型肝炎病毒產品中的一部分專利權可提供持續的資金支持給Enanta的運營。請訪問http://www.enanta.com
Glecaprevir, a protease inhibitor discovered by Enanta, is part of one of the leading treatment regimens for curing chronic hepatitis C virus infection (HCV) and is sold by AbbVie in numerous countries under the trade names MAVYRET(U.S.) and MAVIRET(ex-U.S.) (glecaprevir/pibrentasvir). A portion of Enanta's royalties from HCV products developed under its collaboration with AbbVie contribute ongoing funding to Enanta's operations. Please visit http://www.enanta.com for more information.
https://www.businesswire.com/news/home/20240529474424/en/http://www.enanta.com關於Calix
View source version on businesswire.com: https://www.businesswire.com/news/home/20240529474424/en/
在businesswire.com上查看原始版本businesswire.com: https://www.businesswire.com/news/home/20240529474424/en/
Media and Investors:
Jennifer Viera
jviera@enanta.com
媒體和投資者：Jennifer Viera
jviera@enanta.com
資料來源：Enanta製藥公司。
Source: Enanta Pharmaceuticals, Inc.
來源：Enanta製藥股份有限公司。
譯文內容由第三人軟體翻譯。